This is a Phase 2, open-label study designed to assess the safety and efficacy of setmelanotide in patients with obesity due to Prader-Willi Syndrome (PWS) who are 6 to 65 years of age. Up to 20 patients are planned to be enrolled. Patients will…
- Investigator
- Jennifer L Miller
- Ages
- 6 Years - 65 Years
- Sexes
- All